Performance Improvement Unit for Pulsed-Ultraviolet Devices
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 62/769,779, filed Nov 20, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,811,208 | Performance Improvement Unit for Pulsed-Ultraviolet Devices In force · High confidence UsedRemaining | Pulse RX Disinfection Corp. | In force | High confidence | ||
| US 11,587,753 | Performance Improvement Unit for Pulsed-Ultraviolet Devices In force · High confidence | Pulse RX Disinfection Corp. | In force | High confidence | ||
| US 11,955,303 | Performance Improvement Unit for Pulsed-Ultraviolet Devices In force · High confidence | Pulse RX Disinfection Corp. | In force | High confidence | ||
| US 12,394,584 | Performance Improvement Unit for Pulsed-Ultraviolet Devices In force · High confidence | Pulse RX Disinfection Corp. | In force | High confidence | ||
| Application 19/280,443 | Performance Improvement Unit for Pulsed-Ultraviolet Devices Pending Not granted | Pulse RX Disinfection Corp. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Pulse RX Disinfection Corp..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.